SpainSpain

Digna Biotech regains rights for inhibitor for systemic skin sclerosis

15.11.2011

Madrid/Barcelona – It was a rare example of a partnership between the two competing regions of Castile and Catalonia. Now the alliance between Digna Biotech and ISDIN has come to an end. Digna Biotech announced that it has reached an agreement with ISDIN to regain full rights to Disitertide peptide’s (P144) topical formulation for the therapy of skin conditions. Disitertide is a TGF-β1 (Transforming Growth Factor-Beta 1) inhibitor that has completed a Phase IIa trial for topical treatment of skin systemic sclerosis. “We will run this trial while also validating a primary end-point for a topical treatment on the disease as there is no one at present", said Digna's CEO Pablo Ortiz. In 2005 and 2006, EMA and FDA already had granted Disitertide (P144) Orphan Drug Designation to treat systemic sclerosis and localised scleroderma. Systemic sclerosis or scleroderma is a multi-systemic disorder characterised by the excessive synthesis and deposition of extracellular matrix proteins that leads to the fibrosis of skin and visceral organs. Digna Biotech is a University of Navarra’s spin-off biotech company funded by a group of investors representing some of the major corporations and financial institutions in Spain. It has its headquarters in Madrid.

SpainSpain

04.11.2010

Seville – Genetrix S.L. and the Botín Foundation will channel a 6m over the next three years into the new company Axontherapix SL. The public-private partnership will seek to develop an effective therapy for Parkinson’s Disease....

SpainSpain

03.11.2010

Pamplona – With a record-setting Biospain this year, the Spanish biotech industry has underpinned its role as a premier player in the sector in southern Europe. More than 1,400 business representatives flocked to Pamplona, where...

SpainSpain

28.09.2010

Bilbao – Spanish Progenika Biopharma S.A has gained the green light for sale of its LPLchip in Europe. The DNA chip, which has achieved the CE mark, detects approximately 120 mutations in the lipoprotein lipase (LPL) gene and...

SpainSpain

22.09.2010

Madrid – Responding to the current debate surrounding the reactome array investigation, Manuel Ferrer from the Institute of Catalysis and Petrochemistry in Madrid told EuroBiotechNews his team would “clarify all the scientific...

SpainSpain

09.09.2010

Madrid – When Chinese Premier Wen Jiabao met his Spanish colleague Jose Luis Rodriguez Zapatero on August 31st, he talked about the Mediterranean country’s role as an important economic partner for China, and said cooperation...

SpainSpain

04.08.2010

Madrid/Braunschweig - Spanish and German scientists who last year reported a groundbreaking technology that is able to identify the whole set of biochemical reactions in bacteria or cells, together with the enzymes involved, have...

SpainSpain

11.07.2010

Barcelona – While the cash-strapped Spanish government is being stripped of its AAA grade investment rating, one of the giants of the country’s life science industry is on a spending spree. Grifols, a producer of plasma protein...

SpainSpain

09.07.2010

Barcelona/Nantes – Biomarker-specialist TcLand Expression in Nantes has found an ally in the Vall d’Hebron University Hospital Research Institute (HVIR) in Barcelona. The French company and the Spanish clinic will work together...

SpainSpain

08.06.2010

Barcelona/Triangle Park – Spanish producer of plasma protein therapies Grifols is to acquire US public biopharmaceutical company Talecris, in a deal worth approximately $3.4 billion (EUR2.8 billion). The merger will improve...

Displaying results 21 to 30 out of 181

< Previous 21-30 Next >

© 2007-2014 BIOCOM

http://www.european-biotechnology-news.com/nc/news/messages-archive/archive-spain/browse/2/article/digna-biotech-regains-rights-for-inhibitor-for-systemic-skin-sclerosis.html

Product of the week

Products

Events

All Events

Current issue

All issues